anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Disseminated non-tuberculous mycobacteria (dNTM) infections are mostly reported among individuals with an underlying congenital or acquired immunodeficiency or receiving immunosuppressive treatment, but are rarely documented in otherwise healthy subjects.
CASE PRESENTATION: We describe a case of recurrent disseminated mycobacterial infection in an apparently immunocompetent Chinese woman. Mycobacterium szulgai and Mycobacterium avium-complex were identified in distinct episodes. Long-term antimycobacterial therapy was administered given the occurrence of recurrent events when off-treatment. Successful management over more than 10 years and immunologic data are reported.
CONCLUSIONS: This case-report highlights that dNTM should be suspected also among apparently immunocompetent hosts and that thorough assessment of underling immune-impairments is helpful to define patients' management. Long-term antimycobacterial therapy and close monitoring is required to grant successful outcomes in case of recurrent dNTM infections.
Postcholecystectomy syndrome (PCS) is persistent distressing symptoms which develops following a laparoscopic cholecystectomy (LC); in cases when the condition is severe, readmission may be necessary. However, research on the prevalence of PCS and potential factors associated with PCS in Nepalese patients is still limited. An observational point-prevalence, correlational predictive cross-sectional study was conducted to determine the prevalence of PCS and examine what predicting factors including preoperative anxiety, preoperative dyspepsia, smoking, alcohol consumption, and duration of preoperative symptoms are associated with PCS. A total of 127 eligible Nepalese patients who came for follow-up after 1 week of LC at outpatient department of surgery in one single university hospital, Kathmandu, Nepal, were recruited. A set of questionnaires consisting participants' information record form, Hospital Anxiety and Depression Scale (HADS), Leeds Dyspepsia Questionnaires (LDQ), Fagerstrom Test for Nicotine Dependence (FTND), and Alcohol Use Disorder Identification Test (AUDIT) was administered for data collection. The associations between influential factors and PCS were analyzed using Binary logistic regression. 43.3% of participants reported PCS after 1 week of surgery. The findings from logistic regression analysis affirmed that the patients with preoperative anxiety (OR = 6.38, 95%CI = 2.07-19.67, p < 0.01) and moderate to severe dyspepsia (OR = 4.01, 95%CI = 1.34-12.02, p < 0.05) held the likelihood to report PCS 6.38 and 4.01 times, respectively, greater than others. The implications from study results are that screening of anxiety and patients' tailored interventions to reduce anxiety should be implemented preoperatively. An appropriate health education about persistence of PCS and self-management should be provided to those postoperative patients.
The invention discloses a preparation method of boron-carbon-containing quantum dots and application of the boron-carbon-containing quantum dots in tumor diagnosis and boron neutron capture treatment medicines, and relates to the field of chemical and biomedical tumor diagnosis and treatment. Glucose and BPA are used as raw materials to synthesize boron-containing carbon quantum dots (BCDs), and the BCDs have in vivo and in vitro fluorescence luminescence properties similar to those of carbon quantum dots. Experiments prove that the BCDs synthesized by using glucose and BPA as raw materials can target brain tumors and other tumor tissues and are enriched at tumor sites, and the BCDs in healthy tissues can be rapidly metabolized and excreted. This property provides conditions for achieving excellent therapeutic effects of BNCT. Therefore, BCDs can be used as a novel BNCT therapeutic agent for tumors, and can realize the integration of tumor diagnosis and BNCT therapy. The boron-carbon-containing quantum dots have good biocompatibility and excellent in-vivo fluorescence imaging effect.
FIELD: biotechnology, medicinal microbiology. SUBSTANCE: strain is isolated from youngster feces who intook milk fermented with culture Lactobacillus acidophilus INMIA-9602 (ER 317/402 "Narine") in the process and after course of therapy with antibiotics by selection of isolates showing resistance to antibiotics. Strain multiplicates actively in nutrient media used in production of eubiotical preparations. After 12-14 h of culturing strain increases biomass up to 8-9 lg of microbe cells/1 ml. Strain can develop in concentration of sodium chloride up to 6%, it shows resistance to drying and storage. Strain shows antagonistic activity with respect to pathogenic and opportunistic microorganisms and survives in the presence of some antibiotics. The limit of acidity of milk fermentation at 37 C is 140 T for 3 days. Strain shows expressed antagonistic activity and salt tolerance and has the more homogeneous cells. Invention can be used in medicine and biotechnology for preparing probiotic preparations of medicinal design and fermented-milk products for curative-dietetic nutrition. EFFECT: strain indicated above, high productivity, valuable properties. 5 tbl
This invention relates to a stimulating bone regenerating micro capsule, the capsule is made as following method. (1) Recombination adenovirus carries bone form occurrence albumen. (2) Cultivation of mesenchyme stem cell between bone marrows. (3) Adenovirus carrier transfection bone marrows mesenchyme stem cell that carries osteogenesis gene. (4) microencapsulation of mesenchyme stem cell between bone marrows of bone form occurrence albumen gene transfection. Its advantages are that non-self body stem cell is allowed to use as target cell of gene transfection, so the time of amplification cultivation get from body stem cell. It is used for emergency patient, and can be filtrated out of body, so the quality of cell can be confirmed, and the application range of cell and gene curing can be extended.
Once the patient ends phase II of the cardiac rehabilitation program, he/she will receive the usual care, which consists of a 5-minute educational intervention by a physiatrist at the end of the functional test, where recommendations are given on healthy lifestyle habits, adherence to pharmacological treatment and regular aerobic exercise. This educational intervention will be performed after each of the functional tests (at the end of phase II of the program and during the follow-up of patients at months 1, 3, 6 and 12 during Phase III of the program) performing 5 educational interventions in total .
Type 1 diabetes mellitus (T1DM) results from autoimmune destruction of the insulin-producing pancreatic beta-cells. The onset of clinical symptoms represents the endpoint of a chronic progressive decline in beta-cell function when the number of functional beta-cells descends below the critical mass required for maintenance of euglycemia (\[1\], \[2\]). However, the pancreas still retains the ability to produce a substantial amount of insulin. The goal of secondary prevention in T1DM is to avert further destruction of the remaining beta-cells and therefore delay or stop entry into the final stages of the disease associated with end organ damage.

The rationale for this study is to interfere with the autoimmune beta-cell destruction early on in order to preserve as much residual endogenous insulin production as possible. We plan to administer oral interferon-alpha (IFN-a) on a daily basis, which has been shown to modify the clinical course of diabetes, to alter cytokine release, and reduce expression of T cell activation markers in an animal model (\[3\]) and a pilot project in humans (S. Brod, University of Texas, unpublished data). The one-year study is designed as a double blind randomized protocol using either 5,000 or 30,000 units of IFN-a versus placebo. Five centers will participate in this protocol (University of Texas Health Science Center in Houston; Dallas; Children's Hospital, St. Paul, MN; Kansas City and NIH, Bethesda, Maryland).
Inhibiting the activation and proliferation (DNA synthesis) of human T-lymphocytes or mononuclear cells and the production of TH2 cytokines comprises combined administration of dipeptidyl peptidase IV (DP IV) inhibitors and alanyl-aminopeptidase (aminopeptidase N, APN) inhibitors. The DP IV and APN inhibitors may be replaced by enzymes with the same substrate specificity. Independent claims are also included for the following: (1) the combined use of DP IV and APN inhibitors for the (super-)additive inhibition of the activation and proliferation (DNA synthesis) of human epidermal and follicular keratinocytes and those in the transition region between the skin and mucosa; (2) the combined use of DP IV and APN inhibitors, X-Pro-aminopeptidase (APP) inhibitors, ACE inhibitors and/or prolyloligopeptidase (POP) inhibitors for the (super-)additive inhibition of the activation and proliferation (DNA synthesis) of human T-lymphocytes or mononuclear cells; and (3) pharmaceutical preparations containing DP IV and APN inhibitors (or enzymes with the same substrate specificity) and optionally APP, ACE and/or POP inhibitors. ACTIVITY : Antiinflammatory; Immunosuppressive; Antiarteriosclerotic; Antipsoriatic; Dermatological; Virucide; Cytostatic. MECHANISM OF ACTION : Dipeptidyl peptidase inhibitor; Alanyl-aminopeptidase inhibitor; X-Pro-aminopeptidase inhibitor; Acetylcholine esterase inhibitor; Prolyloligopeptidase inhibitor. Human peripheral T-lymphocytes were incubated for 72 hours in the presence of Lys[Z(NO 2)]-thiazolidide (DP IV inhibitor) and actinoin (APN inhibitor), after which 3>[H]-thymidine incorporation was measured to determine the extent of DNA synthesis. Results showed a dosage-dependent (super-)additive inhibition of DNA synthesis.
FIELD: medicine. SUBSTANCE: method involves irrigating rhinopharynx by means of low frequency ultrasonic radiation produced by an apparatus with 0.01% Miramistin solution with Dimexin added in 50:1 ml concentration, respectively. Irrigation lasts for 1-5 min including pause time. Then, rhinopharyngeal mucous membrane is treated with ultrasonic radiation by means of apparatus wave guide end face during 3-5 s 2-3 mm far from mucous membrane. EFFECT: enhanced effectiveness of treatment. 2 cl, 1 dwg
PROBLEM TO BE SOLVED: To obtain a new compound useful as an intermediate for producing a 3-(1,2,4-oxadiazol-3-yl)-5,6,7,8-tetrahydro-1,6-naphthyridine derivative which is an agonistic agent for benzodiazepine receptors. SOLUTION: This compound is represented by formula I (R1 is H, an acryl, a lower alkyl, etc., with the proviso that R1 is not methyl) or its acid addition salt, e.g. 6-benzyl-5,6,7,8-tetrahydro-2(1H)-oxo-1,6-naphthyridine-3-carbonitrile. The compound is obtained by reacting, e.g. a compound represented by formula II [(n) is 1-3] with a compound represented by formula III (Y is a halogen, a lower alkoxy, etc.; Z is cyano) in a solvent such as dioxane at 0-120 deg.C, then reacting the resultant product with ammonia in a solvent such as ethanol at 0-100 deg.C, subsequently treating the prepared product in the presence of a base in a solvent at 0-100 deg.C and then reacting the product with sodium nitrite under acidic conditions such as a 5-10% aqueous solution of hydrochloric acid at 0-20 deg.C.
Ketoflo to be incorporated into each participant's usual ketogenic diet for 28 days. Amount taken and frequency of intake to be determined by the dietitian.
PURPOSE: A natural plant mixture extract with anti-inflammation and irritation relief is provided to suppress iNOS activation and COX-2 gene expression. CONSTITUTION: A cosmetic composition for anti-inflammation, irritation relief, and immunity enhancement contains mixture extract of prunus persica Batsch roots, Prunus salicina var. salicina roots, Prunus mume Sieb. et Zucc roots, and Juglans regia L. shells as an active ingredient. The mixture extract is obtained using water, low alcohol of 1-4 carbon atoms, propylene glycol, glycerin, or butylene glycol. The composition is manufactured in the form of skin softener, skin toner, astringent, lotion, milk lotion, UV protection lotion, hand cream, foundation, emulsion foundation, essence, pack, soap, cleansing lotion, cleansing cream, or body cleanser.
The purpose of this study is to develop and test educational modules designed to instruct students how to assess the quality and strength of mother-child relationships. The approach will use constructs of Emotional Connection that were used in development of an investigational observation-based screening instrument, the Welch Emotional Connection Screen (WECS). The WECS allows healthcare providers to rate the emotional connection of a mother-child relationship in just a few minutes of observed face-to face interaction, and shows preliminary predictive properties when performed in the first year of life.

Administration of the WECS involves watching recorded interactions of a child sitting face-to-face on the mother's lap, and scoring the interaction on sliding scales per 4 domains. During the WECS development, the Nurture Science Program of Columbia University Irving Medical Center created and coded hours of parent-child interaction videos. These videos will be used to assess and train the students (subjects) on rating mother/child dyads around emotional connection. Subjects will rate the quality of mother-child relationships in video training sets after completing one of two educational modules: A) a lecture-style webinar describing evidence base and instructions on how to score the WECS B) a guide written in Clear Explicit Translatable Language (CETL). Training set results of students in these groups will be compared to results of students who received no prior training. Training set results will be analyzed for the reliability statistic between student scores and key scores established by writer of the scale and PI. Subjects will then spend 3 months without further training in emotional connection or practice coding WECS. Subjects will then rate the quality of mother-child relationships for videos of dyads they hadn't previously seen. The main outcome of this study is the comparison of reliability statistics and maintenance between students who completed different educational modules.
A capsule endoscope system includes a capsule endoscope, swallowable in a body, for forming an image. A receiver is positioned on the body, for wirelessly receiving the image from the capsule endoscope, to store the image. A workstation as information manager operates for image filing of the image from the receiver. A first wireless interface is incorporated in the receiver, for wirelessly transmitting the image during imaging with the capsule endoscope. A second wireless interface is positioned on the workstation, for wirelessly receiving the image from the first wireless interface. Furthermore, an image selector selects the image for image filing in the workstation among plural images received by the receiver. The first wireless interface transmits the selected image to the workstation. The receiver includes an image compressor for reducing a data size of the image received from the capsule endoscope before transmission in the first wireless interface.
A method for preparing the Sargasso nano lipid carrier, comprising the following steps. First, take 2 g Sargasso powder coupled with 100 ml of pure water, and ultrasonic vibration pulverizer to obtain ultrasound extracts were. Then, take 2 g Sargasso powder coupled with 100 ml of pure water, and microwave heating to obtain microwave extracts were. Then, the ultrasonic extracts were mixed with the microwave extracts were to give the Sargasso extracts were. Then, take the solid lipid lanolin, liquid lipids rice bran oil, and a surfactant mixed into the mixture. Then, take the Sargasso extracts were mixed with the mixture, and homogenized to obtain Sargasso emulsion. Finally, the use of a pulverizer ultrasound emulsification ultrasonic vibration, to obtain the Sargasso nano lipid carrier.
BACKGROUND: Fatigue is significant in the context of Parkinson's disease (PD), considering that one-third of patients classify it as the most restricting symptom in their daily life activities (DLAs). The objective was to verify the relationship (association) between fatigue and non-motor and motor symptoms of PD.
METHODS: A cross-sectional study which included 100 individuals with PD. Initially, demographic and clinical data (modified Hoehn and Yahr scale-HY, anxiety, and depression) were collected. To assess the non-motor and motor symptoms of PD, the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) was applied. Fatigue was evaluated using the Parkinson Fatigue Scale.
RESULTS: A higher HY score, greater severity of non-motor aspects of DLAs and motor aspects of DLAs, more motor complications, and higher levels of anxiety as well as depression were observed in the "fatigue" group. Fatigue was associated with a lower daily equivalent levodopa dose (LEDD), a higher body mass index (BMI), anxiety, depression, and the presence of non-motor symptoms.
CONCLUSION: Non-motor symptoms are more determining factors for fatigue than the motor condition itself, with an association between fatigue and higher BMI scores, increased anxiety and depression, lower LEDD, and greater severity of non-motor aspects of DLAs. Individuals in the "fatigue" group had higher HY scores, anxiety, and depression, worse non-motor and motor symptoms related to experiences of daily life, as well as motor complications.
The investigators will implement the pancreaticoduodenectomy using the principle of "Total Peripancreas Excision" to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node.
The present invention provides methods of treating bacterial infections with metal thiolate complexes, such as auranofin. Disclosed herein are methods of treating a bacterial infection in a subject, comprising administering a metal thiolate complex, wherein the metal thiolate complex is cytotoxic to a bacteria. The bacteria may be a gram-positive bacteria. The gram-positive bacteria may be of a Mycobacterium genus. The gram-positive bacteria may be of a Bacillus genus. The gram-positive bacteria may be of an Enterococcus genus. The gram-positive bacteria may be Mycobacterium tuberculosis. The gram-positive bacteria may be Bacillus subtilis. The gram-positive bacteria may be selected from Enterococcusfaecium and Enterococcusfaecalis. The gram-positive bacteria may be Staphylococcus aureus. The Staphylococcus aureus may be resistant to a drug. The drug may be an antibiotic agent selected from vancomycin and linezolid.
Consecutive patients with severe mitral stenosis and clot in left atrial appendage (LAA) on transesophageal echocardiography fulfilling the inclusion criteria will be recruited for this study. An ACUSON 128-XP echocardiographic system equipped with omniplane and biplane transesophageal probes will be used for this study. TEE followed by CT Angiography will be performed according to the standard procedure after obtaining informed consent.
Organ transplantation is currently recognised as the treatment of choice for patients with end-stage renal disease (ESRD), which is an underestimated but increasing burden worldwide. Despite the pressing need for improving patients risk stratification raised by transplant societies as well as regulatory agencies, no risk-stratification system exists that adequately predicts transplant patients' individual risk of allograft loss. This currently represents a limitation for improving patient management, as well as for defining early surrogate end points for clinical trials and development of pharmaceutical agents. The inventors now report the development and validation of an integrative risk prediction score to predict kidney allograft survival of individual patients (NCT03474003). The iBox risk prediction score is the first integrative system validated in several independent populations from Europe & North America as well as across 3 clinical trials (NCT01079143, Eudra CT2007-003213-13, NCT01873157) covering distinct clinical scenarios. In particular, the advantages brought by the iBox risk prediction score are i) improved discrimination performance by combining traditional prognostic factors with mechanistically informed parameters, ii) outperformance when compared with currently existing scoring systems, iii) generalisability when assessed in geographically distinct cohorts from Europe and North America, iv) transportability at different times of evaluation post-transplant, v) performance in a variety of clinical scenarios including clinical trials and vi) readily accessible to clinicians and patients by an online tool for patient risk calculation. Thus, the present invention relates to a method of predicting whether a kidney transplant recipient is at risk of having allograft loss by implementing the iBox risk prediction score.
Disclosed are encapsulating methods and encapsulated products. A payload material may be encapsulated within a wall material. The carrier material and payload material form a combination that is at least substantially solid at room temperature but that is sufficiently fluid at milling temperature to permit milling and subsequent encapsulation. The payload material may be, for instance, a bitter tasting material. In some embodiments, the microcapsules will serve a taste masking function. In other embodiments, the microcapsules may be used where a slow release of the payload material is desired.
The present invention relates to a vaccine for immunizing a cat against feline viruses. The present invention also relates to a nucleic acid clone that encodes the capsid protein of the isolated feline calicivirus. The present invention further relates to a live or killed vaccine comprising the isolated feline calicivirus, a subunit vaccine comprising the capsid protein of the isolated feline calicivirus, a nucleic acid vaccine comprising a nucleic acid clone of the isolated feline calicivirus, and a recombinant virus vector vaccine comprising nucleic acid encoding the capsid protein of the isolated feline calicivirus. The present invention also relates to a method for identifying a feline calicivirus useful for producing a vaccine composition and for assays for diagnosing cats infected with feline calicivirus. Also disclosed is a method of immunizing animals, especially cats, against disease, in particular against feline calicivirus (FCV). The method includes administering to a cat therapeutically effective amounts of first and second FCV vaccines. The first vaccine is administered orally or parenterally (e.g., subcutaneously, intramuscularly, and the like). The second vaccine is administered orally or oronasally N days following administration of the first vaccine, wherein N is an integer from 3 to 120, inclusive. A third vaccine administration may also be given. The present invention also describes methods and materials for treating and immunizing animals with vaccine, and in particular cats against both FPV or Feline Parvovirus, which has also been called Panleukopenia or FPL and against another disease, FHV or Feline Herpes Virus, which has also been called Feline Rhinotracheitis Virus.
Patients in the group B(n=57) intralesional bleomycin alone after taking aseptic and antiseptic measuresThe intralesional dose of bleomycin was 1 mg/kg/dose but for haemangiomas on neck and face it was used as 0.5 mg/kg/dose.The Length, Width, Height and volume of haemangioma was measured in centimeters using a vernier calliper. The decrease in size was graded from 1-5 where 1=\<50% decrease, 2=50-75%, 3=75-90%, 4=\>90% but \<100% and 5= 100% resolution. The data collection sheet included patent's age, sex, length, width, height, volume, site of haemangioma, dose of bleomycin, dexamethasone, clinical response being efficacious or non-efficacious as per operational definition and time taken to resolve for each patient.